Genexine vs Umlaut.bio
Genexine vs Umlaut.bio, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Genexine is on 47/100 and Umlaut.bio on 35/100.
Where each one leads
Genexine
- our overall score: 47/100 against 35/100
- domain rating: 32/100 against 7/100
- funding raised: $297M against $3.0M
Umlaut.bio
- agent readiness: 37/100 against 28/100
At a glance
| Measure | Genexine | Umlaut.bio |
|---|---|---|
| What it is | South Korean biopharmaceutical company developing novel biologics for cancer and rare diseases. | Developing novel immunotherapies for cancer. |
| Category | Biotechnology, HealthTech, Drug Discovery, Immunotherapy | Biotechnology, Cancer, Immunotherapy, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Platform |
| Founded | 1999 | 2022 |
| Headquarters | Seoul, South Korea | Cambridge, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Genexine | Umlaut.bio |
|---|---|---|
| Total funding | $297M | $3.0M |
| Latest round | Funding | Pre-Seed |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Genexine | Umlaut.bio |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 47/100 | 35/100 |
| Traction | 40/100 | 32/100 |
| Team | 50/100 | Not published |
| Search visibility | 5/100 | 8/100 |
| Quality | 58/100 | 48/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (28/100) | F (37/100) |
| Domain ratingLink authority, 0-100 | 32/100 | 7/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Genexine | Umlaut.bio |
|---|---|---|
| Hosting | Not detected | Self Managed |
Genexine vs Umlaut.bio: common questions
Which is better, Genexine or Umlaut.bio?
On our 0-100 score Genexine rates higher (47/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.
How do Genexine and Umlaut.bio compare on the numbers?
Genexine leads on our overall score (47/100 against 35/100), domain rating (32/100 against 7/100), funding raised ($297M against $3.0M). Umlaut.bio leads on agent readiness (37/100 against 28/100).
Read the full Genexine review and pricing or the Umlaut.bio review and pricing. You can also browse other Genexine alternatives we track.